{
    "Clinical Trial ID": "NCT01299038",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Rosuvastatin 20mg",
        "  Rosuvastatin 20mg taken orally once a day for 4 weeks",
        "  rosuvastatin: Taken orally once a day for 4 weeks",
        "INTERVENTION 2: ",
        "  Rosuvastatin 40mg",
        "  Rosuvastatin 40mg taken orally once a day for 4 weeks",
        "  rosuvastatin: Taken orally once a day for 4 weeks"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Metastatic adenocarcinoma of the breast (Stage IV)",
        "  Actively receiving endocrine therapy for at least 6 weeks (with or without HER2 therapy)",
        "  Minimum age 18 years",
        "  ECOG Performance status of 0, 1 or 2",
        "  Normal organ and marrow function as defined in the protocol",
        "Exclusion Criteria:",
        "  Participants may not be receiving any other study agents",
        "  Actively receiving chemotherapy (exclusive of hormonal or HER2 therapy ) within last 5 weeks",
        "  Any statin therapy within the last 3 weeks",
        "  Asian decent (including Filipino, Chinese, Japanese, Korean, Vietnamese or Asian-Indian origin)",
        "  Concomitant use of the following drugs: cyclosporine, fibrates, niacin, gemfibrozil, ketaconazole, spironolactone, cimetidine, warfarin, erythromycin, or protease inhibitors",
        "  Conditions predisposing to renal failure secondary to rhabdomyolysis",
        "  Recent history of heavy alcohol use as judged by the treating physician",
        "  Known to be pregnant (testing not required) or nursing",
        "  History of rhabdomyolysis on statin therapy",
        "  Known history of Hepatitis C or active hepatitis B infection (baseline testing not required)",
        "  Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, hepatitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Mean Change of Tissue Factor Bearing Microparticles",
        "  Comparison of plasma microparticle concentration between baseline and week 4",
        "  Time frame: 4 weeks",
        "Results 1: ",
        "  Arm/Group Title: Rosuvastatin 20mg",
        "  Arm/Group Description: Rosuvastatin 20mg taken orally once a day for 4 weeks",
        "  rosuvastatin: Taken orally once a day for 4 weeks",
        "  Overall Number of Participants Analyzed: 8",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: microparticles per microliter  102         (586)",
        "Results 2: ",
        "  Arm/Group Title: Rosuvastatin 40mg",
        "  Arm/Group Description: Rosuvastatin 40mg taken orally once a day for 4 weeks",
        "  rosuvastatin: Taken orally once a day for 4 weeks",
        "  Overall Number of Participants Analyzed: 7",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: microparticles per microliter  -618         (624)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 0/9 (0.00%)",
        "Adverse Events 2:",
        "  Total: 0/10 (0.00%)"
    ]
}